0 01/10/2023 24/03/2025 2025-03-24 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2023-10-01 Sage Accounts Production 25.0 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 1267027 2023-10-01 2025-03-24 1267027 2025-03-24 1267027 2023-09-30 1267027 2022-10-01 2023-09-30 1267027 2023-09-30 1267027 2022-09-30 1267027 bus:RegisteredOffice 2023-10-01 2025-03-24 1267027 bus:LeadAgentIfApplicable 2023-10-01 2025-03-24 1267027 bus:Director1 2023-10-01 2025-03-24 1267027 bus:Director2 2023-10-01 2025-03-24 1267027 bus:CompanySecretary1 2023-10-01 2025-03-24 1267027 core:WithinOneYear 2025-03-24 1267027 core:WithinOneYear 2023-09-30 1267027 bus:Director1 2023-09-30 1267027 bus:Director1 2025-03-24 1267027 bus:Director1 2022-09-30 1267027 bus:Director1 2023-09-30 1267027 bus:Director1 2022-10-01 2023-09-30 1267027 bus:Micro-entities 2023-10-01 2025-03-24 1267027 bus:AuditExempt-NoAccountantsReport 2023-10-01 2025-03-24 1267027 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2025-03-24 1267027 bus:PrivateLimitedCompanyLtd 2023-10-01 2025-03-24 1267027 bus:FullAccounts 2023-10-01 2025-03-24
Company registration number: 1267027
Denbond Pharmaceuticals Limited
Unaudited filleted financial statements
24 March 2025
Denbond Pharmaceuticals Limited
Contents
Directors and other information
Statement of financial position and notes to the financial statements
Denbond Pharmaceuticals Limited
Directors and other information
Directors Mr A H Rajani (Deceased on 17 November 2024)
Mrs R Rajani
Secretary Mr A Rajani
Company number 1267027
Registered office 24 Malcolm Drive
Off Langley Avenue
Surbiton
Surrey KT6 6QS
Accountants Nagle James Associates Ltd
4th Floor, Amba House
15 College Road
Harrow
Middlesex
HA1 1BA
Bankers Lloyds TSB
1 Claremont Road
Surbiton
Surrey, KT6 4QS
Denbond Pharmaceuticals Limited
Statement of financial position
24 March 2025
24/03/25 30/09/23
£ £
Fixed assets - 2,407
_______ _______
Current assets 52,216 166,299
Creditors: amounts falling due within one year ( 54,790) ( 105,253)
_______ _______
Net current (liabilities)/assets ( 2,574) 61,046
_______ _______
Total assets less current liabilities ( 2,574) 63,453
Accruals and deferred income ( 6,557) ( 5,175)
_______ _______
Net (liabilities)/assets ( 9,131) 58,278
_______ _______
Capital and reserves ( 9,131) 58,278
_______ _______
Notes to the financial statements
Denbond Pharmaceuticals Limited
Period ended 24 March 2025
1. Directors advances, credits and guarantees
During the period the directors entered into the following advances and credits with the company:
Period ended 24/03/25
Balance brought forward Advances /(credits) to the directors Balance o/standing
£ £ £
Mr A H Rajani ( 75,909) 21,119 ( 54,790)
_______ _______ _______
Year ended 30/09/23
Balance brought forward Advances /(credits) to the directors Balance o/standing
£ £ £
Mr A H Rajani ( 74,670) ( 1,239) ( 75,909)
_______ _______ _______
For the period ending 24 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsiblities:
- The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476.
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The financial statements have been prepared in accordance with the micro-entity provisions and have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
These financial statements were approved by the board of directors and authorised for issue on 09 September 2025 , and are signed on behalf of the board by:
Mrs R Rajani
Director
Company registration number: 1267027
The company is a private company limited by shares, registered in England.